Clinical trial NCT00613626: Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
Official title: A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Small Cell Lung Cancer
Keywords: Extensive Stage
Untreated
Lead sponsor: Hoosier Cancer Research Network
Sponsor class: OTHER
Collaborators: name: AstraZeneca
First posted: 2008-02-13
Enrollment: 74
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: At this point in the treatment of extensive stage SCLC, we have reached a plateau in survival with conventional chemotherapy and newer regimens are greatly needed. It has been noted that patients with increased VEGF levels have a poorer prognosis. Anti-angiogenic agents hold significant promise in the treatment of patients with extensive stage SCLC. ZD6474, a new inhibitor of the VEGFR-2, has shown favorable action in NSCLC.

Detailed description: OUTLINE: This is a multi-center study.

Arm A:

Cisplatin 60mg/m2 Day 1 + Etoposide 120mg/m2 Day 1,2,3 + Placebo oral daily given continuously for the duration of the study

Arm B:

Cisplatin 60mg/m2 Day 1 + Etoposide 120mg/m2 Day 1,2,3 + ZD6474 100mg oral daily given continuously for the duration of the study

For both arms, PE and toxicity evaluation prior to each cycle and disease assessment by imaging every 2 cycles. Patients with non-PD and acceptable toxicity will continue protocol therapy; patients with progressive disease or excessive toxicity will be taken off treatment. Cycles will be repeated every 21 days up to a total of 4 cycles.

ECOG Performance Status of 0 or 1

Life Expectancy: Not specified

Hematopoietic:

* Platelets \> 100K/mm3
* Absolute neutrophil count (ANC) \> 1.5K/mm3

Hepatic:

* Bilirubin \< 1.5 x ULN
* Aspartate aminotransferase (AST) \< 2.5 x ULN or \< 5 x ULN if judged by the investigator to be related to liver metastases
* Alkaline phosphatase \< 2.5 x ULN or \< 5 x ULN if judged by the investigator to be related to liver metastases

Renal:

* Serum creatinine \< 1.5 x ULN or Calculated creatinine clearance of \> 45 cc/min using the Cockcroft-Gault formula

Cardiovascular:

* No clinically significant cardiac event such as myocardial infarction; New York Heart Association (NYHA) classification of heart disease \>2 (see SPM) within 3 months prior to registration for protocol therapy
* No presence of cardiac disease that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia.
* No history of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is permitted.

Eligibility criteria: Inclusion Criteria:

* Histological or cytological proof of chemotherapy-naïve, extensive, small cell lung cancer.
* Measurable disease according to RECIST and obtained by imaging within 28 days prior to being registered for protocol therapy.
* Written informed consent and HIPAA authorization for release of personal health information.
* Age 18 years or older at the time of consent.
* Potassium ≥4.0 mmol/L and \<5.5mmol/L (supplementation is allowed).
* Calcium within normal range (supplementation is allowed).
* Magnesium within normal range (supplementation is allowed).

Exclusion Criteria:

* No prior EGFR inhibitor or antiangiogenic agent allowed.
* No prior hormonal therapy.
* No symptomatic brain metastasis.
* No clinically significant infections as judged by the treating investigator.
* No evidence of severe or uncontrolled other systemic disease or any concurrent condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol.
* No previous history of QTc prolongation as a result of medication that required discontinuation of that medication.
* No congenital long QT syndrome or known 1st degree relative with unexplained sudden death under 40 years of age.
* No presence of left bundle branch block (LBBB.)
* No QTc with Bazett's correction that is unmeasurable, or ≥480 msec on screening ECG obtained within 7 days prior to registration for protocol therapy. If a subject has QTc ≥480 msec on screening ECG, the screen ECG may be repeated twice (at least 24 hours apart). The average QTc from the three screening ECGs must be \<480 msec in order for the subject to be eligible for the study.
* No concomitant (within 14 days prior to registration for and during protocol therapy) medication associated with Torsades de Pointes or cause QTc prolongation, is allowed. Medications that prolong QT, but are not strictly associated with Torsades, are allowed if medically necessary and will require increased ECG and electrolyte monitoring.
* No uncontrolled hypertension (systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg).
* No currently active diarrhea that may affect the ability to absorb ZD6474.
* No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, Gleason \< grade 7 prostate cancers, or other cancer for which the subject has been disease-free for at least 5 years.
* Major surgery must be completed greater than 28 days prior to registration for protocol therapy and healed surgical incision is required.
* No concomitant (within 14 days prior to registration for and during protocol therapy) medications that are potent inducers (rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital and St. John's Wort) of CYP3A4 function.
* Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 8 weeks after treatment discontinuation.
* Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy.
* Females must not be breastfeeding.

Primary outcomes:
measure: Time to Disease Progression - Median Time to Progression and Log-Rank Test
timeFrame: 24 months
Secondary outcomes:
measure: Percentage of Participants With Grade 3/4 Hematologic and Non-Hematologic Toxicities
timeFrame: 6 weeks (2 Cycles)
measure: Measure the Response Rate (CR + PR) in Each Arm
timeFrame: 24 months
measure: Measure Disease Control Rate (CR + PR+ SD) in Each Arm
timeFrame: 24 months
measure: Measure Overall Survival for Each Arm
timeFrame: 24 months
measure: Assess VEGF Polymorphisms and Correlate Subject Response
timeFrame: 24 months
Other outcomes:
Locations:
city: Newark
country: United States
facility: Helen F. Graham Cancer Center
state: Delaware
city: Chicago
country: United States
facility: Northwestern University Feinberg School of Medicine
state: Illinois
city: Galesburg
country: United States
facility: Medical & Surgical Specialists, LLC
state: Illinois
city: Bloomington
country: United States
facility: Cancer Care Center of Southern Indiana
state: Indiana
city: Evansville
country: United States
facility: Oncology Hematology Associates of SW Indiana
state: Indiana
city: Fort Wayne
country: United States
facility: Fort Wayne Oncology & Hematology, Inc
state: Indiana
city: Indianapolis
country: United States
facility: IN Onc/Hem Associates
state: Indiana
city: Indianapolis
country: United States
facility: Indiana University Simon Cancer Center
state: Indiana
city: Indianapolis
country: United States
facility: St. Vincent Hospital & Health Centers
state: Indiana
city: Lafayette
country: United States
facility: IU Health Arnett Cancer Center
state: Indiana
city: Lafayette
country: United States
facility: Horizon Oncology Researcg
state: Indiana
city: Muncie
country: United States
facility: IU Health at Ball Memorial Hospital
state: Indiana
city: Munster
country: United States
facility: Monroe Medical Associates
state: Indiana
city: South Bend
country: United States
facility: Northern Indiana Cancer Research Consortium
state: Indiana
city: Terre Haute
country: United States
facility: Providence Medical Group
state: Indiana
city: Omaha
country: United States
facility: Methodist Cancer Center
state: Nebraska
city: Mount Holly
country: United States
facility: Hematology Oncology Associates S.J., P.A.
state: New Jersey
city: Portland
country: United States
facility: Providence Portland Medical Center
state: Oregon
city: Philadelphia
country: United States
facility: Pennsylvania Oncology-Hematology Associates
state: Pennsylvania
Study officials:
affiliation: Hoosier Oncology Group, Inc.
name: Nasser Hanna, M.D.
role: STUDY_CHAIR
References:
citation: Rachel E. Sanborn, Jyoti D. Patel, Gregory A. Masters, Nagesh Jayaram, Anthony W. Stephens, Michael J. Guarino, Jamal Ghazi Misleh, Corinne E. Williams, Jingwei Wu, Nasser H. Hanna. A randomized double-blind phase II trial of platinum (P) plus etoposide (E) with or without concurrent ZD6474 (Z) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC): Hoosier Oncology Group LUN06-113. J Clin Oncol 32:5s, 2014 (suppl; abstr 7506)